Goldline Pharmaceutical SME IPO Details
Goldline Pharmaceutical IPO will open from 12 May 2026 to 14 May 2026. Established in 2005, the company is engaged in marketing pharmaceutical products under its “Goldline” brand across segments like general medicine, cardiology, diabetology, pediatrics, and wellness. The company follows an asset-light business model by outsourcing manufacturing to third-party pharma manufacturers while focusing on branding and distribution. Goldline has a strong presence across multiple Indian states, with operations mainly based in Nagpur, Maharashtra.
IPO Review
IPO GMP
IPO Subscription Subscription
IPO Summary
What is the Goldline Pharmaceutical IPO Timetable?
Track the IPO schedule and key events.
| Event | Date | Day |
|---|---|---|
| IPO Open Date | 12 May, 2026 Tue | Tuesday |
| IPO Close Date | 14 May, 2026 Thu | Thursday |
| Basis of Allotment | 15 May, 2026 Fri | Friday |
| Refunds Initiated | 18 May, 2026 Mon | Monday |
| Credit to Demat | 18 May, 2026 Mon | Monday |
| Listing Date | 19 May, 2026 Tue | Tuesday |
What is the Goldline Pharmaceutical IPO Lot Size?
Bidding in multiples of 3000 shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 6000 | ₹2,58,000 |
| Retail (Max) | 2 | 6000 | ₹2,58,000 |
| HNI (Min) | 3 | 9000 | ₹3,87,000 |
About Goldline Pharmaceutical
The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.
Objects of the Issue
| Issue Object | Estimate Amount |
|---|---|
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | ₹8.90 Cr. |
| General corporate purposes |
Strengths & Risks
Strengths
- ✓ Asset-light business model reduces manufacturing costs and improves operational scalability significantly.
- ✓ Diversified pharmaceutical portfolio caters to multiple therapeutic and healthcare treatment segments.
- ✓ Strong doctor and distributor network supports consistent product demand across regions.
- ✓ Experienced promoters with pharmaceutical industry knowledge help drive business expansion plans.
Risks
- ⚠ Dependence on third-party manufacturers may impact product quality and timely supply.
- ⚠ Highly competitive pharmaceutical industry can pressure margins and market share growth.
- ⚠ Revenue concentration in domestic markets increases dependence on Indian pharmaceutical demand.
- ⚠ Regulatory changes in healthcare sector may affect operations and product approvals.
- ⚠ Smaller business scale compared to major pharma companies limits competitive advantages currently.
Company Financials
Summary of financial performance including revenue, profit, and debt levels will be populated here.
Promoters and Shareholding Details
| Particular | % Share |
|---|---|
| Promoter Holding Pre Issue | 79.70 |
| Promoter Holding Post Issue | -- |
Frequently Asked Questions
What is the GMP of Goldline Pharmaceutical?
The current Grey Market Premium (GMP) of Goldline Pharmaceutical is ₹ 0.
What is the Goldline Pharmaceutical IPO Price Band?
The price band for Goldline Pharmaceutical IPO is 43.
When is the Goldline Pharmaceutical IPO Allotment?
The allotment date for Goldline Pharmaceutical IPO is May 15, 2026.
How to check Goldline Pharmaceutical IPO Allotment Status?
You can check the allotment status on the IPO Allotment Status page or on the registrar's website (Bigshare Services Pvt.Ltd.).
Registrar
Bigshare Services Pvt.Ltd.
Discussion 0
No comments yet
Be the first to share your thoughts!